TCS introduced TCS ADD AgentHub, a new AI platform in this area, which aims to enable pharmaceutical companies to use specialized AI agents for specific business and clinical workflows and deliver new, customized AI agents in critical business and clinical applications with more control over AI agents. It is another step in the direction of agentic AI which is the technology model in which AI systems are programmed to do specific tasks on demand rather than just respond to a single user’s request.
TCS is positioning AgentHub as a platform to automate repetitive work of pharmaceutical companies, and allow them to focus on governance, oversight, and complex decision making in the company’s own work and the human hand.
The pharmaceutical industry has become a key area of enterprise AI development because companies deal with huge amounts of data during the drug development process. Clinical trials bring data from patients, investigators, laboratories, hospitals and technology systems and regulatory requirements require accurate documentation and careful oversight.
Managing this information manually can take a huge amount of time and resources. AI agents could help organisations process information faster, while still keeping human supervision with issues that require expert judgment.
TCS says AgentHub is built around role-specific AI agents that can be embedded in different workflows. Rather than one general AI system for all activities, the platform can be used for specific tasks by using specialised agents dedicated to those tasks in which specific work can be done. This approach is to make AI adoption more realistic for large pharmaceutical organisations where departments in different departments have different processes, regulations and data requirements.
One of the areas where TCS is pointing to potential benefits is clinical data management. Clinical trials generate volumes of structured and unstructured data which needs to be gathered and reviewed, organised and analyzed.
AI-enabled systems would help to alleviate many repetitive aspects of these processes and potentially reduce administrative burden on clinical data teams. And human experts would continue to make critical decisions, verify results and set governance standards for these processes.
Another area of interest is safety case processing, which is a critical function of pharmaceutical operations. Drug-safety teams deal with reports and information related to possible adverse events related to medicines. Processing these cases will involve a lot of information to sort through, review the relevant information and ensure cases are handled according to established procedures.
TCS says its AI can help accelerate parts of that process and so give the specialists the opportunity to work with more complex cases and oversight in a more time-sensitive way, and it will have better time to work on complex cases.
The emergence of agentic AI is especially important because it represents a departure from the usual automation of an AI system. Traditional automation typically follows some predefined rules, while generative AI can generate or summarise information based on user instructions. Agentic systems attempt to marry AI reasoning and task execution with workflow-specific tasks. In an enterprise environment, this could allow an AI agent to execute a set of related tasks in a defined way and with certain permissions and controls.
For pharmaceutical companies, governance will remain one of the most important considerations. Drug development and clinical research are regulated activities, and so AI-generated outputs cannot simply be accepted without appropriate validation.
Human oversight, auditability, data security and clear accountability will be vital when AI agents are integrated into sensitive healthcare workflows. TCS’s focus on governance and human decision making is a demonstration of the need to maintain these safeguards.
The platform also highlights the increasing convergence between artificial intelligence and specialist industry knowledge. General AI models can be powerful, but pharmaceutical companies often require systems that understand highly specific terminology, workflows and regulatory requirements. Role-specific AI agents could help bridge that gap by focusing on defined business functions rather than trying to handle all possible tasks.
The launch comes as technology companies and pharmaceutical companies look for ways to increase productivity across the drug-development lifecycle. Research and development, clinical trials, regulatory submissions, pharmacovigilance and commercial operations involve a lot of information and routine work. As AI technologies mature, companies are looking to reduce manual work and increase speed and consistency of operations.
TCS could also benefit from the growing demand for enterprise AI solutions. Pharmaceutical companies need more than a single AI application. They need systems that can be integrated into the current technology infrastructure, comply with company policies and work with industry-specific workflows. TCS’s experience in technology consulting and digital transformation would give it an opportunity to help companies integrate AI into existing enterprise environments.
However, the success of AgentHub and similar platforms will depend on their implementation. Pharmaceutical companies will need to determine which tasks are ideal for AI automation and which need to be done by humans. Data quality will also be critical. AI systems depend on the quality and consistency of the data they are processing and poor quality data can lead to inaccurate outputs.
Cybersecurity and privacy will be equally important. Clinical-trial data can contain sensitive data, and drug companies need to protect their systems from unauthorized access. Any AI agent deployment must therefore have strong controls on the access to data, permissions and handling of information. The ability to monitor what an AI agent does and keep an auditable record of its actions could be even more important.
Another potential benefit is scalability. When properly tuned, AI agents could support multiple teams and workflows without the need of staffing that fully manual processes would need. This could be particularly useful for large pharmaceutical firms with multiple clinical programmes across different markets.
AI is unlikely to eliminate the need for highly skilled professionals in highly regulated pharmaceutical operations. Instead, technology might change how those professionals spend their time. Routine information processing and administrative tasks could increasingly be handled by AI, while scientists, clinicians, safety specialists and managers focus on interpretation, oversight, strategy and decisions that require human expertise.
TCS’s launch of AgentHub is therefore part of a broader transformation in pharmaceutical technology at large. AI systems are now seen as an add-on to enterprise workflows and as less of a tool to be done alone than rather more of a tool to be used in a specific enterprise environment. If these platforms can deliver tangible improvements and still be managed well in terms of governance and regulatory compliance, they can become an increasingly important component of the digital infrastructure of the industry.
TCS ADD AgentHub represents TCS’s bet on agentic AI in the pharmacy market. It is an effort to solve some of the industry’s most time-consuming operational problems by combining AI agents with human oversight by combining specialist AI agents with the help of humans.
And as pharmaceutical companies pursue AI in clinical trials and drug development, platforms like AgentHub are likely to be key in determining how quickly the industry shifts to automated, data-driven and intelligent workflows.
